Cui, W. et al. Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy. Braz. J. Med. Biol. Res. 50, e5976 (2017).
Alfaadhel, T. & Cattran, D. Management of membranous nephropathy in western countries. Kidney Dis. (Basel) 1, 126–137 (2015).
Ren, S. et al. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis. PLOS ONE. 12, e184398 (2017).
Beck, L. H. Jr. PLA2R and THSD7A: Disparate paths to the same disease?. J. Am. Soc. Nephrol. 28(9), 2579–2589 (2017).
Natalia, P. et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 21, 697–704 (2010).
Disease, K. Improving global outcomes (KDIGO) glomerular diseases work group KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 100, S1–S276 (2021).
van den Brand, J. A., van Dijk, P. R., Hofstra, J. M. & Wetzels, J. F. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 9, 1066–1073 (2014).
Travis, L. B. et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J. Natl. Cancer Inst. 87, 524–530 (1995).
Angioi, A. et al. Treatment of primary membranous nephropathy: Where are we now?. J. Nephrol. 31, 489–502 (2018).
Falkiewicz, K. et al. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation. Transplant. Proc. 38, 119–122 (2006).
Li, Z. Q., Hu, M. L., Zhang, C. & Wang, Y. M. Efficacy and safety of tacrolimus vs cyclophosphamide for idiopathic membranous nephropathy: A meta-analysis of Chinese adults. J. Huazhong Univ. Sci. Technol. Med. Sci. 35, 623–628 (2015).
Praga, M., Barrio, V., Juarez, G. F. & Luno, J. Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int. 71, 924–930 (2007).
Caro, J. et al. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol. Dial. Transplant. 30, 467–474 (2015).
Yuan, H. et al. Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. Pharmacology 91, 259–266 (2013).
Miao, L., Sun, J., Yuan, H., Jia, Y. & Xu, Z. Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation. Nephrology 11, 449–454 (2006).
Wang, Q., Li, M., Cheng, X. & Xu, G. Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy. Sci. Rep. 11(1), 13274 (2021).
Bobart Shane, A. et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 95, 429–438 (2019).
Nagaitseva, S. S. et al. Newly-diagnosed chronic kidney disease in patients of a therapeutic clinic: The role of GFR calculation by the CKD-EPI formula. Klin. Med. 93(7), 56–61 (2015).
Oh, Y. J., Yang, S. H., Kim, D. K., Kang, S. W. & Kim, Y. S. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS ONE 8(4), e62151. https://doi.org/10.1371/journal.pone.0062151 (2013).
Chen Yang, Xu. et al. The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy. Ren. Fail. 45, 2264939 (2023).
Qian, L. et al. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Ren. Fail. 39, 512–518 (2017).
Shuang, L. et al. Evaluating efficacy and safety of tacrolimus treatment in membranous nephropathy: Results of a retrospective study of 182 patients. Ther. Clin. Risk Manag. 19, 351–360 (2023).
Ramachandran, R. et al. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. Nephrology 21, 139–146 (2016).
Glynne, R. et al. How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis. Nature 403, 672–676 (2000).
Presser, D. et al. Differential kinetics of effector and regulatory T cells in patients on calcineurin inhibitor-based drug regimens. Kidney Int. 76, 557–566 (2009).
Ronco, P. & Debiec, H. Pathogenesis of membranous nephropathy: Recent advances and future challenges. Nat. Rev. Nephrol. 8, 203–213 (2012).
Shengyou, Y., Li, Y., Zhihong, H. & Yuanyuan, M. Influence of tacrolimus on podocyte injury inducted by angiotensin II. J. Renin Angiotensin Aldosterone Syst. 16, 260–266 (2015).
Peng, L. et al. The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4. PLoS ONE 9, e106164 (2014).
Ye, M. et al. Prednisone inhibits the focal adhesion kinase/receptor activator of NF-kappaB ligand/mitogen-activated protein kinase signaling pathway in rats with adriamycin-induced nephropathy. Mol. Med. Rep. 12, 7471–7478 (2015).
Li, Y. et al. Effect of tacrolimus and cyclosporine A on suppression of albumin secretion induced by inflammatory cytokines in cultured human hepatocytes. Inflamm. Res. 55, 216–220 (2006).
Migita, K. et al. FK506 potentiates steroid-induced T-cell apoptosis. Transplantation 64, 1365–1369 (1997).
Ning, Y. M. & Sanchez, E. R. Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin. J. Biol. Chem. 268, 6073–6076 (1993).
Velickovic-Radovanovic, R. et al. Tacrolimus as a part of immunosuppressive treatment in kidney transplantation patients: Sex differences. Gend. Med. 9, 471–480 (2012).
Press, R. R., de Fijter, J. W. & Guchelaar, H. J. Individualizing calcineurin inhibitor therapy in renal transplantation—Current limitations and perspectives. Curr. Pharm. Des. 16, 176–186 (2010).
Migita, K. et al. Apoptosis induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation. 63, 583–587 (1997).
Beck Laurence, H. et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543–1550 (2011).
Vink, C. H., Logt, A. V., van der Molen, R. G., Hofstra, J. M. & Wetzels, J. F. M. Antibody-guided therapy in phospholipase A2 receptor-associated membranous nephropathy. Kidney Int. Rep. 8(3), 432–441. https://doi.org/10.1016/j.ekir.2022.12.003 (2022).
Stefan, G. et al. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy. Ren. Fail. 44(1), 258–268. https://doi.org/10.1080/0886022X.2022.2033265 (2022).
Deng, L. et al. Efficacy and Safety of different immunosuppressive therapies in patients with membranous nephropathy and high PLA2R antibody titer. Front. Pharmacol. 12, 786334. https://doi.org/10.3389/fphar.2021.786334 (2022).
Liu, I. D., Willis, N. S., Craig, J. C. & Hodson, E. M. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD003594.pub6 (2019).
He, L. et al. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. J. Nephrol. 26, 564–571 (2013).
- The Renal Warrior Project. Join Now
- Source: https://www.nature.com/articles/s41598-024-64661-w